Number of the records: 1
Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12®Lactobacillus rhamnosus LGG® in colorectal cancer patients
Title Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12®Lactobacillus rhamnosus LGG® in colorectal cancer patients Author Mego Michal Co-authors Daniš Radoslav Chovanec J. Jurišová Silvia Bystrický Branislav Pörsök Štefan Konkolovský Peter Václav Vladimír Wagnerová Mária Streško Marián Brezinová Bibiana Rečková Mária Suteková Dagmar Pazderová Natália Novisedlaková Mária Zomborská Eva Čierniková Soňa 1978- SAVBIOMED ; SAVEXONK - Biomedicínske centrum SAV SCOPUS RID ORCID Svetlovská Daniela Drgoňa Ľuboš Source document Frontiers in Oncology. Vol. 13 (2023), art. no 1168654 Language eng - English Country CH - Switzerland Note open access URL URL link Document kind rozpis článkov z periodík (rbx) Category ADCA - Scientific papers in foreign journals registered in Current Contents Connect with IF (impacted) Category of document (from 2022) V3 - Vedecký výstup publikačnej činnosti z časopisu Type of document článok Year 2023 Registered in WOS Registered in SCOPUS Registered in CCC DOI 10.3389/fonc.2023.1168654 
article
File name Access Size Downloaded Type License Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12®Lactobacillus rhamnosus LGG® in colorectal cancer patients.pdf available 1.4 MB 5 Publisher's version rok CC IF IF Q (best) JCR Av Jour IF Perc SJR SJR Q (best) CiteScore A rok vydania rok metriky IF IF Q (best) SJR SJR Q (best) 2023 2022 4.7 Q2 1.138 Q2
Number of the records: 1